---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Access and coverage questions"
description: "Access and coverage questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Access and billing. Questions: How is unused Nucala billed after a 40 mg pediatric dose from a vial? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Access and coverage questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Access and coverage questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications: Access and coverage](https://www.evicenter.com/medical-information/nucala/access-and-coverage).

## Access and billing

<a id="nucala-pediatric-wastage-billing"></a>

### How is unused Nucala billed after a 40 mg pediatric dose from a vial?

> “The dose for NUCALA for patients 6-11 years old with severe eosinophilic asthma is 40 mg once every 4 weeks. 
> NUCALA lyophilized powder is only available as a 100-mg vial. Payers may require documentation of wastage  
> on claims.
> •	 Use the JW modifier for claims with unused drugs or biologicals from single-use vials or single-use packages 
> that are appropriately discarded
> AND
> •	 Document the discarded drug or biological in the patient’s medical record when submitting claims with unused 
> Part B drugs or biologicals from single-use vials or single-use packages that are appropriately discarded”

Source: [NUCALA: BILLING AND CODING GUIDE, page 9, captured 2026-11-14](https://www.togetherwithgsk.com/content/dam/brs-pharma-us/togetherwithgsk-v2/en_US/nucala/pdf/nucala-billing-and-coding-guide.pdf#page=9)

> “The following is an example of a pediatric patient who was administered  
> a 40-mg dose from a 100-mg vial of reconstituted lyophilized powder. This 
> example demonstrates billing with the HCPCS code J2182 on two line items of 
> the CMS 1500 Claim Form. One line is for the amount administered to the 
> patient (40 mg) and the other is for the discarded portion (60 mg).”

Source: [NUCALA: BILLING AND CODING GUIDE, page 9, captured 2026-11-14](https://www.togetherwithgsk.com/content/dam/brs-pharma-us/togetherwithgsk-v2/en_US/nucala/pdf/nucala-billing-and-coding-guide.pdf#page=9)

Note: The quotes are from the Together with NUCALA billing and coding guide, linked from the coverage support page.

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
